

Detection of Serum Adiponectin in patients of Chronic Hepatitis C and its relation to the treatment therapy

Thesis Submitted
For partial fulfillment of Master degree in internal medicine

By

Sally Hussein Ibrahim

M.B.B.CH

Faculty of Medicine

Ain-Shams University

Under supervision of

Prof. Khaled Hassan M.Hemida

Prof. of Internal medicine

Faculty of Medicine

Ain-Shams University

Prof. Ahmed Ali Monies

Prof. of Internal medicine

Faculty of Medicine

Ain-Shams University

Dr. Nevine Ibrahim Musa

Lecturer of Internal medicine

Faculty of Medicine

Ain-Shams University

2013

Handwritten signatures and marks at the bottom of the page.

LIST OF ABBREVIATIONS

AASLD	The American Association for the Study of Liver Disease.
ACRP³⁰	Adipocyte complement-related protein of 30 kDa.
ADIPOR¹	Adiponectin receptor 1.
ADIPOR²	Adiponectin receptor 2.
AMPK	α -AMP-activated kinase.
apM¹	Adipose most abundant gene transcript 1.
APRI	The AST-to-platelet ratio index.
CAD	Coronary artery disease.
CAPMAS	Central Agency for Public Mobilization and Statistics.
cEVR	Complete early virologic response.
CHC	Chronic hepatitis C infection.
CLDN¹	Claudin-1.
CVD	Cardiovascular diseases.
EIA	Enzyme immunoassay.
EDHS	The Egyptian Demographic Health Survey.
ER	Endoplasmic reticulum.
ETR	End-of-treatment response.
EVR	Early virologic response.
fAd	Full-length form of adiponectin.
gAd	Globular fragment of adiponectin.
GBP²⁸	Gelatin-binding protein of 28 kDa.
HAART	Highly active antiretroviral therapy.
HBV	Hepatitis B virus.
HCC	Hepatocellular carcinoma.
HCV	Hepatitis C virus.
HIV	Human Immunodeficiency Virus.
HDL	High-density lipoproteins.
HMW	High molecular weight adiponectin.
HOMA	Homeostasis model assessment.

IKKβ	inflammatory mediator I κ B kinase β .
IL-λ	Interleukin λ .
IR	Insulin resistance.
IRS	Insulin receptor substrates.
MHC class	Major Histocompatibility class.
MOHP	The ministry of health and population.
NAT	Nucleic acid tests.
NK	Natural Killer cells.
PAMPs	Pathogen-associated molecular patterns.
PCR	Polymerase chain reaction.
pEVR	Partial early virologic response.
PPAR- α	peroxisome proliferator-activated receptor- α .
PPRE	PPAR response elements.
PPγA	Protein phosphatase γ A.
RdRp	RNA-dependent RNA polymerase.
RVR	A rapid virologic response.
SR-Bλ	Human receptor class B type λ .
SVR	Sustained virological response.
T-Cad	T-cadherin.
TγD	Type γ diabetes.
TGFβ	transforming growth factor β .
Thλ	T helper cells.
TNF-alpha	Tumor necrosis factor –alpha.
TZD	Thiazolidinediones.
U.S.A	United States of America.

Content

	Page
Introduction & Aim of the work.....	١
Review of Literature.....	٥
<u>Chapter (١):</u> Hepatitis C Infection.....	٥
<u>Chapter (٢):</u> Adiponectin.....	٧٦
<u>Chapter (٣):</u> Insulin Resistance (Metabolic Syndrome) in Hepatitis C.....	١٠٢
Patients and methods.....	١٢٤
Results.....	١٣٢
Discussion.....	١٦٢
Summary.....	١٧١
Conclusion.....	١٧٧
Recommendations.....	١٧٨
References.....	١٧٩
Arabic summary.....	

LIST OF TABLES

S	NAME	P
١	Extra hepatic Manifestations of Hepatitis C Virus Infection	٣٦
٢	Reasons to perform a Liver Biopsy in a Patient with Hepatitis C	٤٢
٣	Factors Associated with Progression of Hepatic Fibrosis in Patients with Chronic HCV Infection	٤٩
٤	Persons for Whom HCV Screening is Recommended	٥٥
٥	Key Recommendations for Practice	٥٦
٦	Predictors of Sustained Virologic Response to Treatment for Chronic HCV Infection	٦٤
٧	Contraindications to Therapy with Pegylated Interferon and Ribavirin	٦٧
٨	Predominant Expression of Different Adipokines in Subcutaneous or Visceral Tissue	٩٧
٩	Age and sex distribution of group A	١٣٣
١٠	Laboratory investigations of group A patients	١٣٥
١١	Age and sex distribution of group B	١٣٦
١٢	Laboratory investigations of group B patients	١٣٨
١٣	Age and sex distribution of group C	١٣٩
١٤	Laboratory investigations of group C patients	١٤١
١٥	Adiponectin level difference according to sex distribution among group A patients	١٤٢
١٦	Correlation between Adiponectin level and each of SGPT, serum Albumin, HOMA & viral load	١٤٣
١٧	Adiponectin level difference according to sex distribution among group B patients	١٤٥
١٨	Correlation between Adiponectin level and each of SGPT, serum Albumin & HOMA among group B patients	١٤٦

١٩	Adiponectin level difference according to sex distribution among group C patients	١٤٨
٢٠	Correlation between Adiponectin level and each of SGPT, serum Albumin, HOMA & viral load in group C	١٤٩
٢١	Comparison between patients who didn't receive treatment (A) and patients who received treatment (B,C) as regards SGPT	١٥٢
٢٢	Comparison between patients who didn't receive treatment (A) and patients who received treatment (B,C) as regards S.Albumin	١٥٣
٢٣	Comparison between patients who didn't receive treatment (A) and patients who received treatment (B,C) as regards HOMA	١٥٤
٢٤	Comparison between patients who didn't receive treatment (A) and patients who received treatment (B,C) as regards Adiponectin	١٥٤
٢٥	Comparison between group A & B	١٥٥
٢٦	Comparison between group A & C	١٥٦
٢٧	Comparison between group B & C	١٥٧
٢٨	AUC & ٩٥% CI of Adiponectin (between non treated & treated groups)	١٥٨
٢٩	AUC & ٩٥% CI of Adiponectin (between during treatment (B) & after treatment (C) groups)	١٦٠

LIST OF FIGURES

S	NAME	P
١	Hepatitis C virus in Egypt compared to other countries in the world	٩
٢	Prevalence of chronic hepatitis C infection, ٢٠١٢	١٠
٣	Genome organization of Hepatitis C virus	١٤
٤	Life cycle of hepatitis C virus	١٨
٥	Serologic pattern of acute hepatitis C virus (HCV) infection followed by recovery	٣٣
٦	Natural history of Hepatitis c virus infection	٤٦
٧	Adiponectin molecule	٧٩
٨	List of adipokines	٩٦
٩	biological function of insulin	١٠٥
١٠	dysregulated glucose metabolism	١٠٦
١١	Molecular mechanisms of insulin resistance (IR) in hepatitis C virus (HCV) infection	١١٣
١٢	Pathogenic mechanisms and therapeutic strategies for hepatitis C virus (HCV)-associated insulin resistance	١٢٣
١٣	Sex distribution of group A	١٣٣
١٤	Sex distribution of group B	١٣٦
١٥	Sex distribution of group C	١٣٩
١٦	Linear regression curve showing Correlation between Adiponectin level and HOMA in group	١٤٤

	A	
١٧	Linear regression curve showing Correlation between Adiponectin level and Viral load in group A	١٤٤
١٨	Linear regression curve showing Correlation between Adiponectin and SGPT in group B	١٤٦
١٩	Linear regression curve showing Correlation between Adiponectin and HOMA in group B	١٤٧
٢٠	Linear regression curve showing Correlation between Adiponectin and SGPT in group c	١٤٩
٢١	Linear regression curve showing Correlation between Adiponectin and S. Albumin in group C	١٥٠
٢٢	Linear regression curve showing Correlation between Adiponectin and viral load in group C	١٥٠
٢٣	Linear regression curve showing Correlation between Adiponectin and HOMA in group C	١٥١
٢٤	Comparison between group A & B	١٥٥
٢٥	Comparison between group A & C	١٥٦
٢٦	Comparison between group B & C	١٥٧
٢٧	Roc curve of Adiponectin (between group A and both group B&C)	١٥٩
٢٨	Roc curve of Adiponectin (between group B and group C)	١٦١

INTRODUCTION

Adiponectin is an adipocytokine and suggested to have hepato-protective effect. Recent advances in cell biology have shown that adipocytes produce and secrete several bioactive molecules which are collectively referred to as adipocytokines. An adipocyte-specific secretory protein, adiponectin (*Tary et al., २०१०*).

Adiponectin is the most abundant circulating adipokine and modulates a wide array of biological functions. It was demonstrated to improve insulin resistance and play a role in the prevention of atherosclerosis. In addition to the above actions, adiponectin has several anti-inflammatory effects (*Yamauchi et al., २००३*).

It facilitates the removal of early apoptotic cells by macrophages; it reduces Tumor necrosis factor-alpha (TNF-alpha) production in response to various stresses and antagonizes several of its inflammatory effects. Adiponectin is reported to exert its effects by interaction with specific receptors, termed AdipoR¹ and AdipoR². AdipoR¹ is abundantly expressed in skeletal muscles and

Introduction

has a prominent action to promote lipid oxidation. AdipoR γ is primarily transcribed in liver, where it enhances insulin sensitivity and reduces steatosis (*Josson et al.*, 2009).

Growing evidence suggested that adiponectin can regulate lipid and glucose metabolism and lipid content in hepatocytes. Adiponectin is also known to protect hepatocytes from injury (*Wolf et al.*, 2004).

Data indicates that adiponectin plays an anti-inflammatory role in both acute and chronic inflammatory liver diseases. The observed high plasma adiponectin could reflect an imbalance between its production by adipocytes and metabolism in the liver; that could be suggested from high adiponectin levels in chronic liver diseases might reflect one of the body's inflammatory mechanisms in this condition. The liver may play an important role in its catabolism and thus the elevated plasma levels in cirrhosis are, at least in part, due to decreased hepatic catabolism. Even true hepatic production might be another impact, since studies demonstrated that hepatocytes express significant amounts of adiponectin mRNA after injury (*Tary et al.*, 2009).

Introduction

Another suggested impact for the increased adiponectin in liver cirrhosis is altered hepatic extraction. The increased level of circulating adiponectin in cirrhosis seems to be independent of the underlying etiology. Previous studies demonstrated its elevation in cirrhosis due to hepatitis C, hepatitis B and Primary biliary cirrhosis (*Tary et al.*, ۲۰۱۰).

Siagris et al., (۲۰۰۷) reported in his study is that adiponectin values of patients with chronic Hepatitis C virus infection (HCV) were higher than those of chronic hepatitis B virus infection (HBV) patients, and has been reported also that adiponectin is generally elevated in patients with chronic liver disease than in healthy controls. And in his study reported that there was no difference found in adiponectin values according to HCV genotype.

Tary et al., (۲۰۱۰); reported in his study lack of a correlation between insulin resistance, when tested by homeostasis model assessment (HOMA) , and adiponectin levels in cirrhotic patients, and his findings might indicate that the pathogenesis of insulin resistance in cirrhosis differs from that in patients without liver disease.

Aim of the Work

Aim of the work

Adiponectin possess anti-inflammatory, insulin-sensitizing and anti-atherosclerotic properties. Aim of this study is to assess the levels of serum Adiponectin in different patients of Chronic Hepatitis C infection before, during and after treatment therapy and correlating these levels with markers of metabolic syndrome such as insulin resistance and correlating these levels with treatment therapy of chronic hepatitis C by interferon and ribavirin therapy.

Hepatitis C virus infection

Hepatitis C virus (HCV) is a virus that infects liver. Most people that are infected develop persistent infection. A proportion of people (10-50%) develop progressive liver disease leading ultimately to liver cirrhosis, liver failure and hepatocellular carcinoma. An estimated 180 million people are infected worldwide (*WHO*, 2010).

In Egypt, the following sources of data on hepatitis C are available: death registries, nationwide epidemiological studies, laboratory reports and the blood donor registry data. The Ministry of Health and Population (MOPH) does have a system for the surveillance of 26 communicable diseases including viral hepatitis with monthly reporting by all governments (*MOHP*, 2008).

In 1992, the prevalence of HCV in Egypt was reported to be 10.8% among first-time blood donors (*Kamel et al.*, 1992). Since this discovery, many prevalence estimates of HCV have been reported, mostly from rural communities located in the northern Nile Delta (*Saleh et al.*, 2008).

For more than a decade, Egypt has been widely regarded as having an epidemic, with the highest recorded prevalence of HCV in the world. HCV is currently the most significant public health problem in Egypt (*Alter et al.*, 2007).

CAPMAS (Central Agency for Public Mobilization and Statistics) at 2009, estimates that population of Egypt in 2008 was 77,106,000 million and estimates the incidence was 6,0/1000 persons per year.

The Egyptian Demographic Health Survey (EDHS) in 2009 involved a national probability sample of the resident Egyptian population, estimated an overall anti-HCV antibody prevalence of 14.7%. The number of Egyptians estimated to be chronically infected was 9.8 % (*El-Zanaty et al.*, 2009).

The number of new HCV infections, was 537,066 persons per year. Of these, approximately 90,000 would be in those aged below 20 years (*Miller et al.*, 2010).

More than 90% of HCV isolates from Egyptian patients are of genotype 4 variant, which is significant considering Egypt the highest worldwide prevalence of HCV (10-20%) and an overall seroprevalence that is 10-20.

folds higher than in the United States. In rural areas of Egypt, the prevalence of HCV reaches 24%. Subtype 1a is the dominant variant found in Egypt (*Sanaa et al.*, 2004).

In the United States (U.S.), the prevalence of HCV infection between the years 1999-2002 was 1.6%, equating to about 4.1 million persons positive for antibody to hepatitis C (anti-HCV), 0.7% of who are estimated to be viremic. Hepatitis C is the principal cause of death from liver disease and the leading indication for liver transplantation in the U.S. (*Marc et al.*, 2004).

Hepatitis C is the major cause of chronic hepatitis in the United States. HCV infections accounts for 0.7% of all cases of acute hepatitis and for more than 4.7% of all referrals to active liver clinics. Of new infections, 6.7% occur in intravenous drug users; less than 0.7% of new cases are acquired through sexual exposure; and 1.7% are due to other causes, including occupational or perinatal exposure and hemodialysis. It was reported that HCV is largely responsible for the increase in the incidence of hepatocellular carcinoma (HCC) in the United States during the final decades of the 20th century (*Sandeep, Mukherjee et al.*, 2011).